Nanette Santoro
Concepts (960)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 106 | 2026 | 327 | 21.460 |
Why?
| | Hot Flashes | 40 | 2025 | 92 | 10.390 |
Why?
| | Infertility, Female | 47 | 2024 | 124 | 7.890 |
Why?
| | Estrogen Replacement Therapy | 37 | 2026 | 144 | 7.610 |
Why?
| | Menstrual Cycle | 41 | 2026 | 145 | 6.380 |
Why?
| | Women's Health | 44 | 2026 | 317 | 6.100 |
Why?
| | Perimenopause | 26 | 2025 | 69 | 6.060 |
Why?
| | Follicle Stimulating Hormone | 66 | 2026 | 265 | 5.580 |
Why?
| | Estradiol | 62 | 2026 | 517 | 5.540 |
Why?
| | Polycystic Ovary Syndrome | 36 | 2026 | 190 | 5.440 |
Why?
| | Luteinizing Hormone | 59 | 2026 | 206 | 5.210 |
Why?
| | Ovary | 28 | 2025 | 235 | 5.040 |
Why?
| | Endocrinology | 9 | 2023 | 77 | 4.340 |
Why?
| | Postmenopause | 38 | 2026 | 394 | 4.240 |
Why?
| | Metabolic Syndrome | 17 | 2026 | 364 | 3.730 |
Why?
| | Progesterone | 40 | 2026 | 214 | 3.700 |
Why?
| | Anti-Mullerian Hormone | 16 | 2023 | 62 | 3.580 |
Why?
| | Infertility | 13 | 2024 | 61 | 3.460 |
Why?
| | Reproductive Medicine | 8 | 2023 | 19 | 3.260 |
Why?
| | Live Birth | 23 | 2024 | 81 | 3.240 |
Why?
| | Estrogens | 26 | 2026 | 364 | 3.240 |
Why?
| | Female | 371 | 2026 | 79080 | 3.120 |
Why?
| | Receptors, Neurokinin-3 | 5 | 2025 | 8 | 2.730 |
Why?
| | Ovulation Induction | 30 | 2024 | 68 | 2.670 |
Why?
| | Fertilization in Vitro | 20 | 2026 | 109 | 2.660 |
Why?
| | Obesity | 33 | 2024 | 3123 | 2.630 |
Why?
| | Fertility | 16 | 2024 | 173 | 2.620 |
Why?
| | Primary Ovarian Insufficiency | 14 | 2021 | 40 | 2.620 |
Why?
| | Humans | 393 | 2026 | 145625 | 2.480 |
Why?
| | Vasomotor System | 11 | 2025 | 47 | 2.460 |
Why?
| | Hormones | 13 | 2021 | 134 | 2.400 |
Why?
| | Androgens | 15 | 2021 | 179 | 2.370 |
Why?
| | Diet, High-Fat | 3 | 2026 | 267 | 2.300 |
Why?
| | Luteal Phase | 16 | 2020 | 51 | 2.270 |
Why?
| | Gonadal Steroid Hormones | 16 | 2026 | 143 | 2.240 |
Why?
| | Reproduction | 9 | 2022 | 208 | 2.110 |
Why?
| | Aging | 30 | 2025 | 1983 | 2.050 |
Why?
| | Adult | 204 | 2026 | 40821 | 2.050 |
Why?
| | Estrogens, Conjugated (USP) | 16 | 2026 | 52 | 2.020 |
Why?
| | Heterocyclic Compounds, 2-Ring | 8 | 2024 | 18 | 1.980 |
Why?
| | Biomarkers | 36 | 2025 | 4329 | 1.930 |
Why?
| | Ovarian Follicle | 11 | 2025 | 78 | 1.840 |
Why?
| | Thiadiazoles | 8 | 2024 | 25 | 1.820 |
Why?
| | Pregnanediol | 14 | 2026 | 23 | 1.800 |
Why?
| | Endometrium | 15 | 2020 | 64 | 1.740 |
Why?
| | Cryopreservation | 6 | 2024 | 115 | 1.730 |
Why?
| | Ovulation | 14 | 2018 | 46 | 1.680 |
Why?
| | Depression | 13 | 2024 | 1566 | 1.670 |
Why?
| | Fertility Agents, Female | 14 | 2022 | 23 | 1.640 |
Why?
| | Testosterone | 24 | 2021 | 419 | 1.620 |
Why?
| | Menopause, Premature | 4 | 2021 | 12 | 1.620 |
Why?
| | Pregnancy | 74 | 2026 | 7217 | 1.610 |
Why?
| | Pregnancy Rate | 22 | 2024 | 83 | 1.540 |
Why?
| | Cardiovascular Diseases | 24 | 2026 | 2218 | 1.510 |
Why?
| | Hypothalamo-Hypophyseal System | 6 | 2024 | 204 | 1.480 |
Why?
| | Double-Blind Method | 35 | 2025 | 2064 | 1.470 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2024 | 154 | 1.440 |
Why?
| | Quality of Life | 19 | 2026 | 3187 | 1.430 |
Why?
| | Hormone Replacement Therapy | 9 | 2022 | 107 | 1.430 |
Why?
| | Sexual Dysfunction, Physiological | 9 | 2018 | 74 | 1.430 |
Why?
| | Longevity | 2 | 2025 | 179 | 1.390 |
Why?
| | Estrone | 12 | 2026 | 41 | 1.380 |
Why?
| | Infertility, Male | 11 | 2022 | 69 | 1.370 |
Why?
| | Middle Aged | 132 | 2026 | 36359 | 1.330 |
Why?
| | Carotid Intima-Media Thickness | 10 | 2021 | 75 | 1.310 |
Why?
| | Mental Health | 3 | 2024 | 771 | 1.310 |
Why?
| | Premenopause | 14 | 2022 | 129 | 1.250 |
Why?
| | Body Mass Index | 35 | 2026 | 2446 | 1.240 |
Why?
| | Amenorrhea | 12 | 2017 | 35 | 1.210 |
Why?
| | Gonadotropin-Releasing Hormone | 16 | 2022 | 215 | 1.200 |
Why?
| | Sleep Wake Disorders | 8 | 2026 | 314 | 1.190 |
Why?
| | Vaginal Diseases | 3 | 2020 | 19 | 1.160 |
Why?
| | Vagina | 3 | 2020 | 202 | 1.150 |
Why?
| | Endocrinologists | 3 | 2023 | 12 | 1.140 |
Why?
| | Hypothalamus | 10 | 2014 | 161 | 1.130 |
Why?
| | Hormone Antagonists | 2 | 2021 | 32 | 1.090 |
Why?
| | Inhibins | 8 | 2018 | 40 | 1.070 |
Why?
| | Pregnancy Outcome | 11 | 2024 | 502 | 1.060 |
Why?
| | Gynecology | 2 | 2021 | 184 | 1.050 |
Why?
| | Embryo Transfer | 10 | 2024 | 45 | 1.050 |
Why?
| | Atherosclerosis | 6 | 2024 | 410 | 1.030 |
Why?
| | Prospective Studies | 47 | 2025 | 8087 | 1.020 |
Why?
| | Endometriosis | 4 | 2022 | 58 | 0.990 |
Why?
| | Anovulation | 7 | 2015 | 9 | 0.990 |
Why?
| | Hyperlipidemias | 5 | 2022 | 120 | 0.980 |
Why?
| | Uterus | 4 | 2019 | 227 | 0.940 |
Why?
| | Randomized Controlled Trials as Topic | 20 | 2024 | 1754 | 0.920 |
Why?
| | Young Adult | 38 | 2026 | 14240 | 0.910 |
Why?
| | Hyperinsulinism | 3 | 2022 | 115 | 0.900 |
Why?
| | Clomiphene | 9 | 2021 | 15 | 0.900 |
Why?
| | Treatment Outcome | 40 | 2024 | 11744 | 0.890 |
Why?
| | Sex Hormone-Binding Globulin | 15 | 2025 | 51 | 0.880 |
Why?
| | Patient Selection | 7 | 2021 | 720 | 0.870 |
Why?
| | Insulin Resistance | 11 | 2025 | 1247 | 0.860 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 81 | 0.850 |
Why?
| | Insulin | 12 | 2025 | 2524 | 0.830 |
Why?
| | Preconception Care | 2 | 2024 | 50 | 0.830 |
Why?
| | Follicle Stimulating Hormone, Human | 3 | 2022 | 14 | 0.820 |
Why?
| | Adipose Tissue | 4 | 2024 | 641 | 0.810 |
Why?
| | Adipokines | 1 | 2024 | 56 | 0.810 |
Why?
| | Fertility Preservation | 1 | 2024 | 57 | 0.800 |
Why?
| | United States | 52 | 2026 | 16041 | 0.800 |
Why?
| | Salpingo-oophorectomy | 1 | 2024 | 19 | 0.800 |
Why?
| | Life Cycle Stages | 1 | 2023 | 38 | 0.790 |
Why?
| | Glucose Tolerance Test | 2 | 2024 | 360 | 0.790 |
Why?
| | Biomedical Research | 4 | 2023 | 724 | 0.780 |
Why?
| | Menarche | 2 | 2017 | 53 | 0.780 |
Why?
| | Hypogonadism | 9 | 2024 | 89 | 0.770 |
Why?
| | Longitudinal Studies | 26 | 2026 | 3005 | 0.760 |
Why?
| | Gonadotropins | 5 | 2020 | 44 | 0.750 |
Why?
| | HIV Infections | 17 | 2024 | 3210 | 0.750 |
Why?
| | Weight Loss | 6 | 2024 | 857 | 0.750 |
Why?
| | Irritable Mood | 3 | 2018 | 30 | 0.750 |
Why?
| | Progestins | 4 | 2017 | 67 | 0.750 |
Why?
| | Aromatase | 3 | 2014 | 37 | 0.740 |
Why?
| | Administration, Cutaneous | 13 | 2026 | 127 | 0.730 |
Why?
| | Body Composition | 11 | 2025 | 686 | 0.730 |
Why?
| | Ovarian Reserve | 3 | 2020 | 19 | 0.720 |
Why?
| | Corpus Luteum | 8 | 2017 | 23 | 0.720 |
Why?
| | Pituitary Gland | 6 | 2021 | 148 | 0.720 |
Why?
| | Drug Compounding | 3 | 2021 | 106 | 0.720 |
Why?
| | Leiomyoma | 5 | 2025 | 62 | 0.710 |
Why?
| | Cytokines | 4 | 2024 | 2079 | 0.710 |
Why?
| | Sexual Health | 1 | 2023 | 67 | 0.700 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2021 | 1403 | 0.690 |
Why?
| | Risk Factors | 49 | 2024 | 10840 | 0.680 |
Why?
| | Research Subjects | 1 | 2021 | 42 | 0.670 |
Why?
| | Abortion, Spontaneous | 8 | 2024 | 119 | 0.670 |
Why?
| | Fetal Research | 1 | 2021 | 3 | 0.670 |
Why?
| | Soybean Oil | 1 | 2021 | 15 | 0.670 |
Why?
| | Embryo, Mammalian | 1 | 2022 | 230 | 0.670 |
Why?
| | Federal Government | 1 | 2021 | 23 | 0.660 |
Why?
| | Age Factors | 22 | 2023 | 3321 | 0.660 |
Why?
| | Cohort Studies | 30 | 2024 | 6045 | 0.650 |
Why?
| | Hydrocortisone | 4 | 2022 | 303 | 0.650 |
Why?
| | Lipids | 7 | 2023 | 715 | 0.650 |
Why?
| | Bicycling | 1 | 2021 | 117 | 0.640 |
Why?
| | Hand Strength | 1 | 2021 | 145 | 0.640 |
Why?
| | Sleep Initiation and Maintenance Disorders | 4 | 2018 | 197 | 0.640 |
Why?
| | Pregnancy Complications | 3 | 2024 | 605 | 0.630 |
Why?
| | Adolescent | 49 | 2024 | 22451 | 0.630 |
Why?
| | Symptom Assessment | 2 | 2021 | 137 | 0.630 |
Why?
| | Adiposity | 5 | 2026 | 531 | 0.620 |
Why?
| | Premature Birth | 4 | 2024 | 389 | 0.610 |
Why?
| | Cross-Sectional Studies | 31 | 2026 | 5875 | 0.610 |
Why?
| | Ultrasonography | 6 | 2018 | 788 | 0.600 |
Why?
| | Reproductive Health | 3 | 2023 | 94 | 0.590 |
Why?
| | Phospholipids | 1 | 2021 | 215 | 0.590 |
Why?
| | Obstetrics | 1 | 2021 | 178 | 0.590 |
Why?
| | Feasibility Studies | 1 | 2024 | 1125 | 0.590 |
Why?
| | Practice Guidelines as Topic | 3 | 2016 | 1581 | 0.570 |
Why?
| | Spatial Memory | 1 | 2019 | 27 | 0.570 |
Why?
| | Hysterosalpingography | 1 | 2018 | 9 | 0.560 |
Why?
| | Sexuality | 1 | 2018 | 32 | 0.560 |
Why?
| | Hypothalamic Diseases | 3 | 2017 | 17 | 0.550 |
Why?
| | Ovarian Hyperstimulation Syndrome | 3 | 2008 | 6 | 0.550 |
Why?
| | Cognition | 11 | 2026 | 1286 | 0.550 |
Why?
| | Liver | 4 | 2024 | 1859 | 0.550 |
Why?
| | Sleep | 9 | 2021 | 896 | 0.550 |
Why?
| | Menstruation | 10 | 2024 | 44 | 0.540 |
Why?
| | Thyrotropin | 4 | 2024 | 120 | 0.530 |
Why?
| | Phenotype | 5 | 2024 | 3186 | 0.520 |
Why?
| | Chorionic Gonadotropin | 10 | 2024 | 77 | 0.520 |
Why?
| | Anxiety | 5 | 2024 | 1118 | 0.520 |
Why?
| | Insemination, Artificial | 5 | 2022 | 11 | 0.520 |
Why?
| | Life Style | 10 | 2024 | 495 | 0.520 |
Why?
| | Abortifacient Agents, Nonsteroidal | 3 | 2024 | 20 | 0.510 |
Why?
| | Methotrexate | 5 | 2024 | 234 | 0.500 |
Why?
| | Watchful Waiting | 3 | 2024 | 90 | 0.490 |
Why?
| | Hyperandrogenism | 5 | 2024 | 25 | 0.490 |
Why?
| | Hypopituitarism | 2 | 2014 | 16 | 0.490 |
Why?
| | Health Surveys | 5 | 2011 | 511 | 0.490 |
Why?
| | Military Personnel | 1 | 2024 | 715 | 0.490 |
Why?
| | Hysterectomy | 5 | 2023 | 138 | 0.480 |
Why?
| | Fetus | 1 | 2021 | 798 | 0.480 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 299 | 0.470 |
Why?
| | Pregnancy Trimester, First | 2 | 2019 | 139 | 0.470 |
Why?
| | Substance-Related Disorders | 6 | 2009 | 1098 | 0.470 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2016 | 33 | 0.470 |
Why?
| | Cumulus Cells | 2 | 2015 | 7 | 0.460 |
Why?
| | Levonorgestrel | 1 | 2015 | 34 | 0.450 |
Why?
| | Sweating | 4 | 2018 | 43 | 0.450 |
Why?
| | Uterine Hemorrhage | 3 | 2021 | 41 | 0.440 |
Why?
| | Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.440 |
Why?
| | Circadian Rhythm | 3 | 2017 | 514 | 0.440 |
Why?
| | Azoospermia | 1 | 2015 | 7 | 0.440 |
Why?
| | Overweight | 5 | 2014 | 613 | 0.440 |
Why?
| | Surveys and Questionnaires | 20 | 2022 | 6050 | 0.420 |
Why?
| | Bone Density | 7 | 2011 | 492 | 0.420 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 574 | 0.420 |
Why?
| | Time Factors | 21 | 2025 | 7079 | 0.420 |
Why?
| | Pulsatile Flow | 3 | 2011 | 62 | 0.420 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 109 | 0.410 |
Why?
| | Vulvodynia | 1 | 2014 | 2 | 0.410 |
Why?
| | Granulosa Cells | 4 | 2021 | 37 | 0.410 |
Why?
| | Blood Proteins | 1 | 2015 | 239 | 0.400 |
Why?
| | Nitriles | 5 | 2015 | 211 | 0.400 |
Why?
| | Triazoles | 5 | 2015 | 190 | 0.390 |
Why?
| | Osteoporosis | 1 | 2016 | 239 | 0.380 |
Why?
| | Obesity, Abdominal | 3 | 2026 | 48 | 0.380 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5397 | 0.380 |
Why?
| | Pregnancy, Multiple | 4 | 2015 | 19 | 0.380 |
Why?
| | Pregnancy, Ectopic | 4 | 2024 | 54 | 0.380 |
Why?
| | Cross-Over Studies | 4 | 2022 | 612 | 0.380 |
Why?
| | White Matter | 2 | 2025 | 169 | 0.380 |
Why?
| | Solubility | 2 | 2023 | 240 | 0.370 |
Why?
| | Uterine Neoplasms | 3 | 2025 | 98 | 0.360 |
Why?
| | Parity | 2 | 2011 | 112 | 0.360 |
Why?
| | Prevalence | 14 | 2025 | 2852 | 0.360 |
Why?
| | Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.360 |
Why?
| | Follicular Phase | 12 | 2014 | 41 | 0.360 |
Why?
| | Complementary Therapies | 3 | 2022 | 93 | 0.360 |
Why?
| | Indoles | 1 | 2016 | 509 | 0.350 |
Why?
| | Male | 65 | 2024 | 73014 | 0.350 |
Why?
| | Prolactin | 4 | 2022 | 88 | 0.350 |
Why?
| | Stress, Psychological | 8 | 2018 | 1169 | 0.350 |
Why?
| | Cell Cycle | 1 | 2015 | 595 | 0.350 |
Why?
| | Human Growth Hormone | 2 | 2022 | 46 | 0.340 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 60 | 0.340 |
Why?
| | Intracranial Thrombosis | 1 | 2011 | 19 | 0.340 |
Why?
| | Aged | 26 | 2025 | 26251 | 0.330 |
Why?
| | Fallopian Tubes | 3 | 2018 | 33 | 0.330 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2008 | 278 | 0.330 |
Why?
| | Endocrine System | 1 | 2011 | 22 | 0.330 |
Why?
| | Weight Gain | 5 | 2020 | 561 | 0.320 |
Why?
| | Uterine Diseases | 2 | 2007 | 18 | 0.320 |
Why?
| | Inflammation | 4 | 2024 | 2915 | 0.310 |
Why?
| | Coronary Artery Disease | 4 | 2019 | 751 | 0.310 |
Why?
| | Logistic Models | 14 | 2015 | 2112 | 0.310 |
Why?
| | Activins | 3 | 2005 | 28 | 0.300 |
Why?
| | Regression Analysis | 7 | 2020 | 994 | 0.300 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2021 | 47 | 0.300 |
Why?
| | Odds Ratio | 14 | 2015 | 1070 | 0.300 |
Why?
| | Prognosis | 15 | 2020 | 4331 | 0.300 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1101 | 0.300 |
Why?
| | Oocyte Donation | 1 | 2009 | 6 | 0.290 |
Why?
| | Vulva | 1 | 2009 | 24 | 0.290 |
Why?
| | Trinucleotide Repeats | 1 | 2009 | 31 | 0.290 |
Why?
| | Multivariate Analysis | 13 | 2015 | 1531 | 0.290 |
Why?
| | Exercise | 3 | 2022 | 2206 | 0.290 |
Why?
| | Lactation | 2 | 2024 | 193 | 0.290 |
Why?
| | Incidence | 9 | 2025 | 2910 | 0.280 |
Why?
| | Fertility Agents | 2 | 2020 | 3 | 0.280 |
Why?
| | Luteal Cells | 1 | 2008 | 3 | 0.280 |
Why?
| | Semen | 4 | 2022 | 21 | 0.280 |
Why?
| | Administration, Oral | 8 | 2020 | 867 | 0.280 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 727 | 0.280 |
Why?
| | Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.280 |
Why?
| | Multicenter Studies as Topic | 8 | 2022 | 413 | 0.280 |
Why?
| | Signal Transduction | 3 | 2021 | 5234 | 0.280 |
Why?
| | Administration, Intravaginal | 2 | 2020 | 19 | 0.270 |
Why?
| | Bone Remodeling | 2 | 2008 | 71 | 0.270 |
Why?
| | Ovariectomy | 3 | 2023 | 164 | 0.270 |
Why?
| | Carotid Artery Diseases | 2 | 2020 | 70 | 0.270 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 59 | 0.270 |
Why?
| | Mood Disorders | 3 | 2015 | 129 | 0.270 |
Why?
| | Vitamin D Deficiency | 2 | 2021 | 188 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 4 | 2026 | 3917 | 0.270 |
Why?
| | Mentors | 1 | 2010 | 215 | 0.270 |
Why?
| | Polyps | 1 | 2007 | 13 | 0.260 |
Why?
| | Oocyte Retrieval | 3 | 2015 | 20 | 0.260 |
Why?
| | Metformin | 3 | 2012 | 328 | 0.260 |
Why?
| | Breast Neoplasms | 4 | 2022 | 2411 | 0.260 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2023 | 265 | 0.260 |
Why?
| | Adaptation, Psychological | 3 | 2018 | 718 | 0.260 |
Why?
| | Risk Assessment | 12 | 2024 | 3678 | 0.250 |
Why?
| | Models, Biological | 6 | 2025 | 1758 | 0.250 |
Why?
| | Pericardium | 3 | 2019 | 59 | 0.250 |
Why?
| | Virilism | 1 | 2007 | 6 | 0.250 |
Why?
| | Vitamin D | 3 | 2021 | 402 | 0.250 |
Why?
| | Antioxidants | 2 | 2021 | 544 | 0.250 |
Why?
| | Dehydroepiandrosterone Sulfate | 6 | 2011 | 43 | 0.250 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 169 | 0.240 |
Why?
| | Fertilization | 3 | 2022 | 44 | 0.240 |
Why?
| | Reproductive Techniques | 3 | 2001 | 4 | 0.240 |
Why?
| | Attitude to Health | 3 | 2009 | 419 | 0.240 |
Why?
| | Child | 24 | 2024 | 22638 | 0.240 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2022 | 318 | 0.230 |
Why?
| | Autoimmunity | 2 | 2024 | 924 | 0.230 |
Why?
| | Specimen Handling | 3 | 2018 | 178 | 0.230 |
Why?
| | Metabolome | 1 | 2009 | 390 | 0.230 |
Why?
| | Affect | 3 | 2018 | 317 | 0.230 |
Why?
| | Reference Values | 9 | 2020 | 787 | 0.230 |
Why?
| | New York City | 6 | 2010 | 87 | 0.230 |
Why?
| | Leuprolide | 4 | 1998 | 21 | 0.230 |
Why?
| | Glucose | 3 | 2024 | 1051 | 0.230 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 363 | 0.220 |
Why?
| | Pilot Projects | 5 | 2020 | 1878 | 0.220 |
Why?
| | Atrophy | 2 | 2020 | 199 | 0.220 |
Why?
| | Contraceptive Agents, Female | 2 | 2016 | 80 | 0.220 |
Why?
| | Infant, Newborn | 10 | 2024 | 6449 | 0.220 |
Why?
| | Dehydroepiandrosterone | 5 | 2016 | 50 | 0.210 |
Why?
| | Case-Control Studies | 7 | 2020 | 3633 | 0.210 |
Why?
| | Bariatric Surgery | 1 | 2008 | 248 | 0.210 |
Why?
| | Follistatin | 1 | 2004 | 11 | 0.210 |
Why?
| | Biology | 2 | 2023 | 90 | 0.210 |
Why?
| | Blood Pressure | 5 | 2026 | 1761 | 0.210 |
Why?
| | Recovery of Function | 2 | 2008 | 721 | 0.210 |
Why?
| | Vascular Calcification | 2 | 2019 | 109 | 0.210 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2024 | 7 | 0.210 |
Why?
| | Lipolysis | 1 | 2024 | 44 | 0.210 |
Why?
| | Ideal Body Weight | 1 | 2024 | 4 | 0.210 |
Why?
| | Oxidative Stress | 2 | 2021 | 1367 | 0.210 |
Why?
| | C-Reactive Protein | 4 | 2022 | 427 | 0.210 |
Why?
| | Age of Onset | 3 | 2017 | 557 | 0.210 |
Why?
| | Environmental Pollutants | 1 | 2026 | 142 | 0.210 |
Why?
| | Socioeconomic Factors | 7 | 2013 | 1323 | 0.210 |
Why?
| | Ovum | 1 | 2024 | 30 | 0.200 |
Why?
| | Physical Conditioning, Human | 1 | 2024 | 38 | 0.200 |
Why?
| | Thyroid Gland | 1 | 2024 | 93 | 0.200 |
Why?
| | Alanine Transaminase | 1 | 2024 | 151 | 0.200 |
Why?
| | Embryo Culture Techniques | 1 | 2024 | 11 | 0.200 |
Why?
| | Positron-Emission Tomography | 1 | 2026 | 342 | 0.200 |
Why?
| | Diet, Fat-Restricted | 1 | 2024 | 79 | 0.200 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3930 | 0.200 |
Why?
| | Skin Aging | 2 | 2016 | 20 | 0.200 |
Why?
| | Pediatric Obesity | 2 | 2024 | 635 | 0.200 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 119 | 0.200 |
Why?
| | Academic Medical Centers | 4 | 2021 | 560 | 0.200 |
Why?
| | Focus Groups | 2 | 2024 | 587 | 0.200 |
Why?
| | Blood Glucose | 7 | 2025 | 2357 | 0.200 |
Why?
| | Neoplasms | 4 | 2024 | 2944 | 0.190 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.190 |
Why?
| | Endometrial Hyperplasia | 1 | 2023 | 6 | 0.190 |
Why?
| | Bone Resorption | 2 | 2015 | 80 | 0.190 |
Why?
| | Drug Therapy, Combination | 5 | 2018 | 1034 | 0.190 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1062 | 0.190 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 767 | 0.190 |
Why?
| | Oligomenorrhea | 2 | 2014 | 14 | 0.190 |
Why?
| | Animals | 16 | 2026 | 38030 | 0.190 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 8 | 0.190 |
Why?
| | Dyspareunia | 2 | 2016 | 8 | 0.190 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 251 | 0.190 |
Why?
| | Ovulation Detection | 1 | 2002 | 1 | 0.190 |
Why?
| | Fractures, Bone | 2 | 2008 | 431 | 0.190 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 629 | 0.190 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 2 | 2019 | 25 | 0.190 |
Why?
| | Interleukin-6 | 2 | 2022 | 782 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2024 | 103 | 0.180 |
Why?
| | Asymptomatic Diseases | 3 | 2018 | 102 | 0.180 |
Why?
| | Dilatation and Curettage | 2 | 2021 | 13 | 0.180 |
Why?
| | Brachial Artery | 2 | 2026 | 206 | 0.180 |
Why?
| | Reimbursement Mechanisms | 2 | 2001 | 78 | 0.180 |
Why?
| | Simvastatin | 1 | 2002 | 58 | 0.180 |
Why?
| | Smoking | 6 | 2015 | 1478 | 0.180 |
Why?
| | Cuba | 3 | 2010 | 15 | 0.180 |
Why?
| | Retrospective Studies | 14 | 2024 | 17291 | 0.180 |
Why?
| | Central America | 3 | 2010 | 28 | 0.180 |
Why?
| | Fatty Liver | 1 | 2024 | 251 | 0.170 |
Why?
| | South America | 3 | 2010 | 56 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 79 | 0.170 |
Why?
| | Puerto Rico | 3 | 2010 | 64 | 0.170 |
Why?
| | Germ Cells | 1 | 2022 | 66 | 0.170 |
Why?
| | Goals | 1 | 2023 | 187 | 0.170 |
Why?
| | Washington | 1 | 2022 | 157 | 0.170 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 41 | 0.170 |
Why?
| | Semen Analysis | 4 | 2022 | 15 | 0.170 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 33 | 0.170 |
Why?
| | Inflammation Mediators | 1 | 2024 | 507 | 0.170 |
Why?
| | Health Behavior | 1 | 2007 | 801 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2026 | 488 | 0.170 |
Why?
| | Anti-HIV Agents | 2 | 2005 | 914 | 0.170 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 32 | 0.170 |
Why?
| | Emulsions | 1 | 2021 | 58 | 0.160 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.160 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 632 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 266 | 0.160 |
Why?
| | Referral and Consultation | 3 | 2016 | 878 | 0.160 |
Why?
| | Linear Models | 7 | 2019 | 847 | 0.160 |
Why?
| | Sexual Behavior | 3 | 2016 | 489 | 0.160 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 268 | 0.160 |
Why?
| | Thinness | 1 | 2021 | 99 | 0.160 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 205 | 0.160 |
Why?
| | Genetic Fitness | 1 | 2021 | 60 | 0.160 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 199 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2009 | 2497 | 0.160 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 140 | 0.160 |
Why?
| | Dominican Republic | 2 | 2010 | 29 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 502 | 0.160 |
Why?
| | Vasodilation | 2 | 2026 | 519 | 0.160 |
Why?
| | Spermatozoa | 3 | 2022 | 103 | 0.150 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 120 | 0.150 |
Why?
| | Coitus | 2 | 2022 | 24 | 0.150 |
Why?
| | Drug Combinations | 3 | 2016 | 399 | 0.150 |
Why?
| | Vitamins | 1 | 2021 | 183 | 0.150 |
Why?
| | Electronics | 1 | 2000 | 65 | 0.150 |
Why?
| | Down-Regulation | 5 | 2019 | 612 | 0.150 |
Why?
| | Hypertension | 2 | 2024 | 1270 | 0.150 |
Why?
| | Choice Behavior | 1 | 2021 | 179 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1334 | 0.150 |
Why?
| | Gene Expression | 3 | 2021 | 1461 | 0.150 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 187 | 0.150 |
Why?
| | Growth Hormone | 2 | 2022 | 91 | 0.150 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2011 | 41 | 0.150 |
Why?
| | Puberty | 2 | 2019 | 141 | 0.150 |
Why?
| | Lipoproteins, HDL | 3 | 2015 | 104 | 0.150 |
Why?
| | RNA, Messenger | 6 | 2011 | 2783 | 0.150 |
Why?
| | Ethics, Medical | 1 | 2000 | 90 | 0.150 |
Why?
| | Gonadotropins, Pituitary | 4 | 2011 | 21 | 0.150 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 206 | 0.150 |
Why?
| | Leptin | 3 | 2022 | 247 | 0.150 |
Why?
| | Acculturation | 2 | 2010 | 55 | 0.150 |
Why?
| | Erectile Dysfunction | 1 | 2019 | 35 | 0.150 |
Why?
| | Cell Nucleolus | 2 | 2010 | 21 | 0.150 |
Why?
| | Sulfonamides | 1 | 2023 | 592 | 0.140 |
Why?
| | Adiponectin | 3 | 2022 | 243 | 0.140 |
Why?
| | Decidua | 1 | 2019 | 21 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 899 | 0.140 |
Why?
| | Sperm Count | 4 | 2022 | 17 | 0.140 |
Why?
| | Spermatogenesis | 1 | 2019 | 87 | 0.140 |
Why?
| | Carotid Arteries | 1 | 2020 | 206 | 0.140 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.140 |
Why?
| | Surgeons | 1 | 2023 | 337 | 0.140 |
Why?
| | Allostasis | 1 | 2018 | 17 | 0.140 |
Why?
| | Ovarian Diseases | 3 | 1993 | 14 | 0.140 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 41 | 0.140 |
Why?
| | Waist Circumference | 5 | 2022 | 142 | 0.140 |
Why?
| | Adrenal Glands | 1 | 1998 | 77 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 448 | 0.130 |
Why?
| | Genitalia | 1 | 2018 | 32 | 0.130 |
Why?
| | Feeding Behavior | 1 | 2024 | 691 | 0.130 |
Why?
| | Child Behavior | 1 | 2020 | 234 | 0.130 |
Why?
| | Placebos | 2 | 2015 | 190 | 0.130 |
Why?
| | Periodicity | 8 | 2016 | 57 | 0.130 |
Why?
| | Keratin-18 | 1 | 2017 | 12 | 0.130 |
Why?
| | Religion | 1 | 2018 | 64 | 0.130 |
Why?
| | Precision Medicine | 1 | 2022 | 462 | 0.130 |
Why?
| | Decision Support Techniques | 1 | 2022 | 473 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 751 | 0.130 |
Why?
| | Comorbidity | 5 | 2014 | 1652 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2018 | 279 | 0.120 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2017 | 38 | 0.120 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 33 | 0.120 |
Why?
| | Body Weight | 4 | 2015 | 964 | 0.120 |
Why?
| | Receptors, Leptin | 2 | 2013 | 25 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 724 | 0.120 |
Why?
| | Vaginal Creams, Foams, and Jellies | 1 | 2016 | 4 | 0.120 |
Why?
| | Orgasm | 1 | 2016 | 6 | 0.120 |
Why?
| | Heart | 1 | 2020 | 624 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2018 | 507 | 0.120 |
Why?
| | Disease Progression | 4 | 2020 | 2857 | 0.120 |
Why?
| | Oxytocics | 1 | 2016 | 15 | 0.120 |
Why?
| | Antidepressive Agents | 1 | 2018 | 234 | 0.120 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 230 | 0.120 |
Why?
| | Societies, Scientific | 1 | 2016 | 50 | 0.120 |
Why?
| | Endocrine System Diseases | 1 | 2016 | 35 | 0.110 |
Why?
| | Autoantibodies | 2 | 2024 | 1498 | 0.110 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 162 | 0.110 |
Why?
| | Confidence Intervals | 4 | 2011 | 328 | 0.110 |
Why?
| | Fluoroimmunoassay | 2 | 1999 | 4 | 0.110 |
Why?
| | Causality | 2 | 2014 | 128 | 0.110 |
Why?
| | Health Status | 3 | 2023 | 822 | 0.110 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2218 | 0.110 |
Why?
| | Oxytocin | 1 | 2016 | 51 | 0.110 |
Why?
| | Hirsutism | 2 | 2017 | 12 | 0.110 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 49 | 0.110 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2015 | 27 | 0.110 |
Why?
| | Mutation | 4 | 2013 | 4082 | 0.110 |
Why?
| | Body Constitution | 3 | 2004 | 51 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 133 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2015 | 66 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1790 | 0.110 |
Why?
| | Conserved Sequence | 1 | 1996 | 242 | 0.110 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 452 | 0.110 |
Why?
| | Sequence Alignment | 1 | 1996 | 360 | 0.110 |
Why?
| | Child Development | 1 | 2020 | 481 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2018 | 449 | 0.110 |
Why?
| | Drug Approval | 1 | 2015 | 93 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.110 |
Why?
| | Fetal Growth Retardation | 2 | 2019 | 592 | 0.110 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 67 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1526 | 0.110 |
Why?
| | Societies, Medical | 3 | 2017 | 901 | 0.110 |
Why?
| | Antibodies, Bacterial | 1 | 2015 | 147 | 0.110 |
Why?
| | Infant | 15 | 2024 | 10093 | 0.110 |
Why?
| | Limit of Detection | 1 | 2015 | 92 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 88 | 0.110 |
Why?
| | Survival Analysis | 4 | 2014 | 1372 | 0.110 |
Why?
| | Chlamydia Infections | 1 | 2015 | 79 | 0.110 |
Why?
| | Interferon-alpha | 1 | 1996 | 201 | 0.110 |
Why?
| | Algorithms | 4 | 2011 | 1843 | 0.110 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 307 | 0.100 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 207 | 0.100 |
Why?
| | Migraine Disorders | 1 | 2016 | 109 | 0.100 |
Why?
| | Self Report | 4 | 2026 | 869 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 567 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 207 | 0.100 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 94 | 0.100 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 15 | 0.100 |
Why?
| | Immunoglobulin G | 2 | 2015 | 899 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 333 | 0.100 |
Why?
| | Core Binding Factors | 1 | 2013 | 2 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1223 | 0.100 |
Why?
| | Sperm Motility | 3 | 2022 | 34 | 0.100 |
Why?
| | Laparoscopy | 1 | 2018 | 474 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1996 | 0.100 |
Why?
| | Air Pollution | 1 | 2017 | 314 | 0.100 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2097 | 0.100 |
Why?
| | Creatinine | 3 | 2022 | 511 | 0.100 |
Why?
| | Oocytes | 2 | 2011 | 186 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2015 | 494 | 0.100 |
Why?
| | Bone Marrow Transplantation | 4 | 1999 | 298 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2013 | 73 | 0.100 |
Why?
| | Brain | 1 | 2026 | 2981 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 362 | 0.100 |
Why?
| | Range of Motion, Articular | 1 | 2015 | 437 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2021 | 1208 | 0.090 |
Why?
| | Child, Preschool | 16 | 2020 | 11888 | 0.090 |
Why?
| | Nerve Tissue Proteins | 3 | 2011 | 594 | 0.090 |
Why?
| | Muscle Strength | 1 | 2015 | 332 | 0.090 |
Why?
| | Chi-Square Distribution | 4 | 2015 | 511 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2015 | 351 | 0.090 |
Why?
| | Contraceptives, Oral | 2 | 2003 | 37 | 0.090 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2015 | 8351 | 0.090 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 782 | 0.090 |
Why?
| | Rats | 3 | 2019 | 5574 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 341 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 844 | 0.090 |
Why?
| | Varicocele | 1 | 2011 | 5 | 0.090 |
Why?
| | Methadone | 2 | 2011 | 130 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2015 | 558 | 0.090 |
Why?
| | China | 4 | 2011 | 278 | 0.090 |
Why?
| | Placenta Diseases | 1 | 2011 | 20 | 0.090 |
Why?
| | Tissue Banks | 1 | 2011 | 17 | 0.090 |
Why?
| | Receptors, Somatomedin | 1 | 2011 | 5 | 0.090 |
Why?
| | Receptors, Glucagon | 1 | 2011 | 27 | 0.090 |
Why?
| | Somatomedins | 1 | 2011 | 28 | 0.090 |
Why?
| | Epithelial Cells | 2 | 2009 | 1118 | 0.090 |
Why?
| | Skin | 1 | 2016 | 701 | 0.080 |
Why?
| | Siblings | 2 | 2009 | 196 | 0.080 |
Why?
| | Receptor, trkA | 1 | 2011 | 17 | 0.080 |
Why?
| | Narcotics | 1 | 2011 | 57 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2591 | 0.080 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1236 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 103 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 3 | 2006 | 280 | 0.080 |
Why?
| | Glucagon | 1 | 2011 | 114 | 0.080 |
Why?
| | Skin Physiological Phenomena | 1 | 2010 | 17 | 0.080 |
Why?
| | Pelvic Organ Prolapse | 1 | 2011 | 62 | 0.080 |
Why?
| | Actigraphy | 3 | 2017 | 148 | 0.080 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2010 | 15 | 0.080 |
Why?
| | Superovulation | 3 | 2012 | 7 | 0.080 |
Why?
| | Decision Trees | 1 | 2010 | 75 | 0.080 |
Why?
| | Hip Fractures | 1 | 2011 | 88 | 0.080 |
Why?
| | Waist-Hip Ratio | 2 | 2026 | 37 | 0.080 |
Why?
| | Japan | 3 | 2011 | 149 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 1997 | 1429 | 0.080 |
Why?
| | Environment | 2 | 2003 | 295 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 372 | 0.080 |
Why?
| | Fetal Diseases | 1 | 2011 | 192 | 0.080 |
Why?
| | Career Mobility | 1 | 2010 | 68 | 0.080 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 36 | 0.070 |
Why?
| | Lithium Chloride | 1 | 2009 | 14 | 0.070 |
Why?
| | Glucocorticoids | 1 | 1993 | 536 | 0.070 |
Why?
| | Comprehension | 1 | 2011 | 175 | 0.070 |
Why?
| | Quality Control | 2 | 2000 | 162 | 0.070 |
Why?
| | HIV Seropositivity | 2 | 2011 | 117 | 0.070 |
Why?
| | Blastocyst | 1 | 2009 | 50 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 249 | 0.070 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 15 | 0.070 |
Why?
| | Health Promotion | 1 | 2015 | 786 | 0.070 |
Why?
| | Perception | 1 | 2011 | 372 | 0.070 |
Why?
| | Vaginitis | 1 | 2008 | 2 | 0.070 |
Why?
| | Proteomics | 1 | 2015 | 1202 | 0.070 |
Why?
| | Memory | 1 | 2011 | 298 | 0.070 |
Why?
| | Nuclear Pore | 1 | 2008 | 19 | 0.070 |
Why?
| | Osteoprotegerin | 1 | 2008 | 24 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 2018 | 0.070 |
Why?
| | Sleep Apnea Syndromes | 1 | 2009 | 98 | 0.070 |
Why?
| | Embryo Implantation | 1 | 2008 | 33 | 0.070 |
Why?
| | Birth Weight | 2 | 2024 | 521 | 0.070 |
Why?
| | Uterine Prolapse | 1 | 2008 | 14 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2019 | 1293 | 0.070 |
Why?
| | Coronary Disease | 2 | 2012 | 380 | 0.070 |
Why?
| | Androstenedione | 2 | 1999 | 10 | 0.070 |
Why?
| | Infant, Low Birth Weight | 2 | 2019 | 154 | 0.070 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 466 | 0.070 |
Why?
| | Anthropometry | 1 | 2008 | 203 | 0.060 |
Why?
| | Social Class | 1 | 2009 | 260 | 0.060 |
Why?
| | Data Collection | 1 | 2010 | 647 | 0.060 |
Why?
| | Skin Absorption | 1 | 2007 | 14 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2015 | 956 | 0.060 |
Why?
| | Combined Modality Therapy | 5 | 2021 | 1269 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2007 | 334 | 0.060 |
Why?
| | Receptors, Steroid | 1 | 2007 | 41 | 0.060 |
Why?
| | Cultural Characteristics | 1 | 2007 | 65 | 0.060 |
Why?
| | Interpersonal Relations | 1 | 2010 | 387 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2011 | 489 | 0.060 |
Why?
| | Administration, Topical | 1 | 2007 | 153 | 0.060 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2013 | 700 | 0.060 |
Why?
| | Research Design | 2 | 2011 | 1139 | 0.060 |
Why?
| | Asparaginase | 3 | 2001 | 34 | 0.060 |
Why?
| | Relaxin | 2 | 1998 | 18 | 0.060 |
Why?
| | Patient Satisfaction | 2 | 2021 | 698 | 0.060 |
Why?
| | Proteins | 3 | 1989 | 1021 | 0.060 |
Why?
| | Age Distribution | 2 | 2004 | 395 | 0.060 |
Why?
| | Phthalic Acids | 1 | 2026 | 43 | 0.060 |
Why?
| | Tissue Donors | 1 | 2009 | 398 | 0.060 |
Why?
| | Gonadal Hormones | 1 | 2005 | 8 | 0.060 |
Why?
| | Phosphorylation | 2 | 2021 | 1717 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2009 | 960 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2009 | 533 | 0.060 |
Why?
| | Entropy | 1 | 2025 | 44 | 0.060 |
Why?
| | Preoptic Area | 1 | 2005 | 8 | 0.060 |
Why?
| | Inhibin-beta Subunits | 1 | 2005 | 6 | 0.060 |
Why?
| | Spouses | 1 | 2007 | 105 | 0.060 |
Why?
| | Maternal Age | 2 | 2022 | 129 | 0.060 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 82 | 0.060 |
Why?
| | Phenols | 1 | 2026 | 106 | 0.060 |
Why?
| | Libido | 1 | 2005 | 23 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2005 | 33 | 0.060 |
Why?
| | Stochastic Processes | 1 | 2025 | 64 | 0.060 |
Why?
| | Mathematical Concepts | 1 | 2025 | 35 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 477 | 0.050 |
Why?
| | Internet | 2 | 2015 | 656 | 0.050 |
Why?
| | Blastomeres | 1 | 2004 | 11 | 0.050 |
Why?
| | Iodide Peroxidase | 1 | 2024 | 34 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2014 | 1184 | 0.050 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 268 | 0.050 |
Why?
| | Fluorocarbons | 1 | 2026 | 122 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 512 | 0.050 |
Why?
| | Apoptosis | 2 | 2017 | 2436 | 0.050 |
Why?
| | Nuclear Proteins | 3 | 2022 | 739 | 0.050 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 2 | 2001 | 32 | 0.050 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 276 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2025 | 158 | 0.050 |
Why?
| | Infusions, Intravenous | 3 | 1994 | 429 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2005 | 177 | 0.050 |
Why?
| | Bone Marrow | 1 | 2005 | 308 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2024 | 63 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1318 | 0.050 |
Why?
| | Central Nervous System | 1 | 2005 | 278 | 0.050 |
Why?
| | Sex Characteristics | 3 | 2019 | 798 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2005 | 255 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 285 | 0.050 |
Why?
| | MicroRNAs | 1 | 2009 | 695 | 0.050 |
Why?
| | Elasticity | 2 | 2016 | 187 | 0.050 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 195 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 40 | 0.050 |
Why?
| | Mice | 5 | 2026 | 18266 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 973 | 0.050 |
Why?
| | Mass Screening | 1 | 2011 | 1300 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 147 | 0.050 |
Why?
| | Melphalan | 2 | 1999 | 43 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 15 | 0.050 |
Why?
| | Follicular Atresia | 1 | 2002 | 4 | 0.040 |
Why?
| | Remission Induction | 4 | 2009 | 308 | 0.040 |
Why?
| | alpha-Amylases | 1 | 2022 | 11 | 0.040 |
Why?
| | Whole-Body Irradiation | 2 | 1999 | 73 | 0.040 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2002 | 67 | 0.040 |
Why?
| | Snoring | 1 | 2021 | 19 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2004 | 405 | 0.040 |
Why?
| | Thyroid Hormones | 1 | 2022 | 69 | 0.040 |
Why?
| | Breast | 1 | 2022 | 154 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 34 | 0.040 |
Why?
| | Computers | 2 | 2000 | 65 | 0.040 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2022 | 88 | 0.040 |
Why?
| | Maternal-Child Nursing | 1 | 2001 | 10 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2766 | 0.040 |
Why?
| | Nursing Methodology Research | 1 | 2001 | 43 | 0.040 |
Why?
| | Executive Function | 1 | 2026 | 461 | 0.040 |
Why?
| | X Chromosome | 1 | 2001 | 66 | 0.040 |
Why?
| | Anger | 1 | 2001 | 55 | 0.040 |
Why?
| | Radiography | 2 | 2014 | 856 | 0.040 |
Why?
| | Pulmonary Blastoma | 1 | 2000 | 8 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 130 | 0.040 |
Why?
| | Canada | 1 | 2022 | 430 | 0.040 |
Why?
| | Prevotella | 1 | 2021 | 27 | 0.040 |
Why?
| | Body Surface Area | 1 | 2020 | 33 | 0.040 |
Why?
| | Grief | 1 | 2001 | 52 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 246 | 0.040 |
Why?
| | Insemination | 1 | 2020 | 1 | 0.040 |
Why?
| | Blood Volume | 1 | 2020 | 57 | 0.040 |
Why?
| | Illinois | 1 | 2020 | 47 | 0.040 |
Why?
| | Paper | 1 | 2000 | 9 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 2000 | 31 | 0.040 |
Why?
| | Chicago | 1 | 2020 | 62 | 0.040 |
Why?
| | Gestures | 1 | 2020 | 7 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2809 | 0.040 |
Why?
| | Gestational Age | 1 | 2024 | 989 | 0.040 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 1999 | 6 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2018 | 3396 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 959 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 735 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 519 | 0.040 |
Why?
| | Personal Autonomy | 1 | 2000 | 61 | 0.040 |
Why?
| | Observer Variation | 1 | 2000 | 355 | 0.040 |
Why?
| | Thrombin | 1 | 2000 | 174 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2026 | 952 | 0.040 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 1999 | 76 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 49 | 0.040 |
Why?
| | Base Sequence | 3 | 2001 | 2119 | 0.040 |
Why?
| | Gene Deletion | 1 | 2001 | 384 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2026 | 640 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 291 | 0.040 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 2101 | 0.040 |
Why?
| | Chromosome Breakage | 1 | 1999 | 23 | 0.040 |
Why?
| | Triglycerides | 2 | 2017 | 527 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1999 | 36 | 0.040 |
Why?
| | Chromosome Inversion | 1 | 1999 | 20 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1992 | 0.040 |
Why?
| | Educational Status | 2 | 2012 | 466 | 0.040 |
Why?
| | Energy Metabolism | 2 | 2022 | 930 | 0.040 |
Why?
| | Molecular Sequence Data | 3 | 2001 | 2835 | 0.030 |
Why?
| | Italy | 3 | 2009 | 118 | 0.030 |
Why?
| | Diet | 2 | 2023 | 1271 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 507 | 0.030 |
Why?
| | Hyperthyroidism | 1 | 2018 | 22 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 485 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 447 | 0.030 |
Why?
| | Genetic Testing | 1 | 2001 | 491 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 364 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 1990 | 197 | 0.030 |
Why?
| | Microinjections | 1 | 1998 | 92 | 0.030 |
Why?
| | Insurance, Health | 1 | 2001 | 315 | 0.030 |
Why?
| | Needs Assessment | 1 | 2001 | 403 | 0.030 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 7 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 137 | 0.030 |
Why?
| | Glucuronates | 1 | 2017 | 5 | 0.030 |
Why?
| | Organ Size | 2 | 2010 | 463 | 0.030 |
Why?
| | Neurons | 1 | 2007 | 1663 | 0.030 |
Why?
| | Transaminases | 1 | 2017 | 22 | 0.030 |
Why?
| | Conservative Treatment | 1 | 2018 | 45 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 410 | 0.030 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 11 | 0.030 |
Why?
| | Immunologic Tests | 1 | 1997 | 16 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2004 | 852 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 57 | 0.030 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 300 | 0.030 |
Why?
| | Pregnancy Tests | 1 | 2017 | 11 | 0.030 |
Why?
| | Vehicle Emissions | 1 | 2017 | 57 | 0.030 |
Why?
| | Biopsy | 1 | 2000 | 1073 | 0.030 |
Why?
| | Disease-Free Survival | 4 | 2001 | 777 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 586 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2910 | 0.030 |
Why?
| | Biological Assay | 1 | 2017 | 133 | 0.030 |
Why?
| | Public Health | 1 | 2022 | 573 | 0.030 |
Why?
| | Genes | 1 | 1997 | 215 | 0.030 |
Why?
| | Molecular Weight | 3 | 2013 | 295 | 0.030 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 45 | 0.030 |
Why?
| | Thrombosis | 1 | 2000 | 397 | 0.030 |
Why?
| | Transdermal Patch | 1 | 2016 | 14 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2001 | 2088 | 0.030 |
Why?
| | Hepatitis C | 2 | 2011 | 250 | 0.030 |
Why?
| | Hyperprolactinemia | 1 | 2016 | 6 | 0.030 |
Why?
| | Galvanic Skin Response | 1 | 2016 | 26 | 0.030 |
Why?
| | Goiter | 1 | 1996 | 5 | 0.030 |
Why?
| | Genes, Regulator | 1 | 1996 | 33 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2001 | 692 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 561 | 0.030 |
Why?
| | Serologic Tests | 1 | 2015 | 50 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 2 | 2008 | 131 | 0.030 |
Why?
| | Catheters, Indwelling | 2 | 1993 | 94 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 454 | 0.030 |
Why?
| | Hypothyroidism | 1 | 1996 | 68 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 423 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1996 | 382 | 0.030 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1995 | 36 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1700 | 0.030 |
Why?
| | Genetic Markers | 2 | 2011 | 337 | 0.030 |
Why?
| | Alcohol Drinking | 2 | 2012 | 847 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1999 | 693 | 0.030 |
Why?
| | Deafness | 1 | 1996 | 67 | 0.030 |
Why?
| | Cranial Irradiation | 2 | 2009 | 85 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 189 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1996 | 177 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1066 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 948 | 0.030 |
Why?
| | Certolizumab Pegol | 1 | 2014 | 5 | 0.030 |
Why?
| | Cyclosporine | 1 | 1995 | 256 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1500 | 0.030 |
Why?
| | Etanercept | 1 | 2014 | 60 | 0.030 |
Why?
| | Vincristine | 3 | 2001 | 148 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 165 | 0.030 |
Why?
| | Freezing | 1 | 1994 | 84 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 53 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1511 | 0.030 |
Why?
| | Glycerol | 1 | 1994 | 90 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 55 | 0.030 |
Why?
| | Drug Stability | 1 | 1994 | 168 | 0.020 |
Why?
| | Anions | 1 | 2013 | 29 | 0.020 |
Why?
| | Registries | 2 | 2020 | 2382 | 0.020 |
Why?
| | Qualitative Research | 1 | 2021 | 1720 | 0.020 |
Why?
| | Infliximab | 1 | 2014 | 107 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2014 | 162 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 845 | 0.020 |
Why?
| | Medical Records | 1 | 2014 | 190 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2013 | 141 | 0.020 |
Why?
| | Air Pollutants | 1 | 2017 | 406 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1997 | 728 | 0.020 |
Why?
| | Electrocardiography | 1 | 2016 | 666 | 0.020 |
Why?
| | Cell Survival | 2 | 2007 | 1102 | 0.020 |
Why?
| | Anal Canal | 1 | 1993 | 101 | 0.020 |
Why?
| | Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.020 |
Why?
| | Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.020 |
Why?
| | Coffee | 1 | 2012 | 16 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2011 | 37 | 0.020 |
Why?
| | Women | 1 | 2012 | 46 | 0.020 |
Why?
| | Tea | 1 | 2012 | 17 | 0.020 |
Why?
| | Oogenesis | 1 | 2011 | 20 | 0.020 |
Why?
| | Mutation, Missense | 2 | 2006 | 331 | 0.020 |
Why?
| | Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
| | Rectocele | 1 | 2011 | 4 | 0.020 |
Why?
| | Placentation | 1 | 2011 | 52 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 159 | 0.020 |
Why?
| | Fetal Death | 1 | 2011 | 59 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Alcoholic Beverages | 1 | 2012 | 32 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 207 | 0.020 |
Why?
| | Ulna Fractures | 1 | 2011 | 16 | 0.020 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2011 | 17 | 0.020 |
Why?
| | Nerve Growth Factor | 1 | 2011 | 36 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 202 | 0.020 |
Why?
| | Receptor, trkB | 1 | 2011 | 39 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2010 | 8 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 310 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2011 | 81 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 162 | 0.020 |
Why?
| | Colon | 1 | 1993 | 304 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 129 | 0.020 |
Why?
| | Radius Fractures | 1 | 2011 | 68 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 3 | 0.020 |
Why?
| | Proinsulin | 1 | 2010 | 54 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 277 | 0.020 |
Why?
| | Herpes Zoster | 1 | 2014 | 318 | 0.020 |
Why?
| | Daunorubicin | 2 | 2001 | 25 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 155 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 219 | 0.020 |
Why?
| | Informed Consent | 1 | 2011 | 194 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2001 | 2962 | 0.020 |
Why?
| | Hematology | 1 | 2009 | 21 | 0.020 |
Why?
| | Survival Rate | 2 | 2009 | 2078 | 0.020 |
Why?
| | Infusion Pumps | 1 | 1989 | 33 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2009 | 7 | 0.020 |
Why?
| | Culture Techniques | 1 | 1989 | 65 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4588 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 109 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2009 | 64 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 74 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 649 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 83 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 165 | 0.020 |
Why?
| | Prednisone | 2 | 2001 | 229 | 0.020 |
Why?
| | West Indies | 1 | 2008 | 5 | 0.020 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 6 | 0.020 |
Why?
| | Safety | 1 | 1990 | 346 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 2008 | 15 | 0.020 |
Why?
| | Hyperhidrosis | 1 | 2008 | 6 | 0.020 |
Why?
| | RANK Ligand | 1 | 2008 | 29 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1993 | 627 | 0.020 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 37 | 0.020 |
Why?
| | Menorrhagia | 1 | 2008 | 22 | 0.020 |
Why?
| | Polysomnography | 1 | 2009 | 239 | 0.020 |
Why?
| | Papio | 1 | 2008 | 70 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1824 | 0.020 |
Why?
| | Pelvic Floor | 1 | 2008 | 32 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 992 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 144 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2533 | 0.020 |
Why?
| | Isoenzymes | 1 | 2008 | 294 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 345 | 0.020 |
Why?
| | Collagen Type I | 1 | 2008 | 144 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2007 | 38 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 728 | 0.020 |
Why?
| | Transplantation, Autologous | 2 | 1999 | 303 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 137 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2008 | 249 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2000 | 611 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2000 | 2674 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 196 | 0.020 |
Why?
| | Transplantation Conditioning | 2 | 1999 | 191 | 0.020 |
Why?
| | Medical Oncology | 1 | 2009 | 344 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 840 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 315 | 0.010 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 61 | 0.010 |
Why?
| | New York | 1 | 2006 | 127 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1212 | 0.010 |
Why?
| | Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2010 | 284 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 1136 | 0.010 |
Why?
| | Body Fluids | 1 | 1986 | 70 | 0.010 |
Why?
| | Microdialysis | 1 | 2005 | 56 | 0.010 |
Why?
| | HIV-1 | 1 | 1991 | 911 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2007 | 319 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 794 | 0.010 |
Why?
| | Neoplasm, Residual | 1 | 2005 | 143 | 0.010 |
Why?
| | Stroke | 1 | 2014 | 1283 | 0.010 |
Why?
| | Demography | 1 | 2005 | 274 | 0.010 |
Why?
| | Urban Population | 1 | 2008 | 496 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3121 | 0.010 |
Why?
| | Communication | 1 | 2011 | 979 | 0.010 |
Why?
| | Life Change Events | 1 | 2005 | 144 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 851 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 278 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1553 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2005 | 429 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 991 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4112 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2001 | 26 | 0.010 |
Why?
| | Interviews as Topic | 1 | 2005 | 926 | 0.010 |
Why?
| | Estrus | 1 | 2001 | 14 | 0.010 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 17 | 0.010 |
Why?
| | Rest | 1 | 2001 | 126 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1181 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2000 | 72 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 6021 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 140 | 0.010 |
Why?
| | Pedigree | 1 | 2001 | 507 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 365 | 0.010 |
Why?
| | Transplants | 1 | 1999 | 36 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2000 | 324 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 253 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1429 | 0.010 |
Why?
| | Consanguinity | 1 | 1999 | 50 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2001 | 267 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
| | Thioguanine | 1 | 1998 | 18 | 0.010 |
Why?
| | Cytarabine | 1 | 1998 | 66 | 0.010 |
Why?
| | Leucovorin | 1 | 1998 | 98 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 269 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1998 | 91 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 1998 | 116 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1998 | 275 | 0.010 |
Why?
| | Chromosome Aberrations | 1 | 1998 | 167 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 80 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 526 | 0.010 |
Why?
| | Dexamethasone | 1 | 1998 | 368 | 0.010 |
Why?
| | Introns | 1 | 1997 | 257 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 326 | 0.010 |
Why?
| | Doxorubicin | 1 | 1998 | 414 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1997 | 409 | 0.010 |
Why?
| | Risk | 1 | 1998 | 917 | 0.010 |
Why?
| | Exons | 1 | 1997 | 361 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 377 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1996 | 138 | 0.010 |
Why?
| | Drug Resistance | 1 | 1995 | 145 | 0.010 |
Why?
| | Colostomy | 1 | 1993 | 28 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 1125 | 0.010 |
Why?
| | Testis | 1 | 1994 | 157 | 0.010 |
Why?
| | Liver Diseases | 1 | 1996 | 298 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1993 | 161 | 0.010 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1991 | 13 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2000 | 2455 | 0.010 |
Why?
| | Sarcoma, Kaposi | 1 | 1991 | 82 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 633 | 0.000 |
Why?
| | Feedback | 1 | 1990 | 180 | 0.000 |
Why?
| | Equipment Contamination | 1 | 1989 | 67 | 0.000 |
Why?
| | Forearm | 1 | 1989 | 141 | 0.000 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 369 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1989 | 246 | 0.000 |
Why?
| | Organ Culture Techniques | 1 | 1987 | 150 | 0.000 |
Why?
| | Isoelectric Point | 1 | 1986 | 21 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1991 | 774 | 0.000 |
Why?
| | Bacteria | 1 | 1989 | 766 | 0.000 |
Why?
| | Hemoglobins | 1 | 1986 | 384 | 0.000 |
Why?
|
|
Santoro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|